Arch Venture Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Arch Venture Management’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-30,000	Closed	-$5.45M	–	8
2023 Q1	$5.45M	Sell	30,000 -482,872	-94%	-$92.3M	2.63%	5
2022 Q4	$101M	Sell	512,872 -800,000	-61%	-$172M	25.81%	2
2022 Q3	$295M	Sell	1,312,872 -1,600,000	-55%	-$324M	38.28%	1
2022 Q2	$369M	Hold	2,912,872	–	–	44.91%	1
2022 Q1	$369M	Hold	2,912,872	–	–	52.78%	1
2021 Q4	$382M	Buy	+2,912,872	New	+$376M	40.37%	1

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Arch Venture Management's KRTX Position: Q2 2023 in Review

Arch Venture Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q2 2023, closing a stake of 30,000 shares — an estimated $5.45M sold.

Arch Venture Management first reported a position in KRTX in Q4 2021 and held it in 6 quarters. The position peaked at $382M in Q4 2021. 288 funds tracked by Wall St. Rank hold KRTX as of Q2 2023.

Arch Venture Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Arch Venture Management sold 30,000 Karuna Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $5.45M.
Arch Venture Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Arch Venture Management's Karuna Therapeutics, Inc. Common Stock position peaked at $382M in Q4 2021.
288 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Arch Venture Management's 13F filing for Q2 2023, filed 9 Aug 2023.